Literature DB >> 6160323

Effects of chronic beta-adrenoceptor antagonism on plasma catecholamines and blood pressure in hypertension.

R D Watson, B M Eriksson, C A Hamilton, J L Reid, T J Stallard, W A Littler.   

Abstract

Plasma catecholamines were measured before and after treatment with beta-adrenoceptor antagonists in 17 hypertensive patients. Chronic treatment with beta-adrenoceptor antagonists caused substantial reductions in heart rate and intra-arterial blood pressure recorded continuously during ambulation. Before treatment, a quantitative relationship was observed between plasma norepinephrine and blood pressure and heart rate during a variety of activities; a similar relationship was also observed after chronic treatment five of six patients, suggesting that plasma norepinephrine remains an index of sympathetic activity despite the influence of beta-adrenoceptor antagonism. After treatment, plasma norepinephrine tended to be higher at any level of blood pressure, although not significantly so. Chronic treatment caused no significant change in mean resting plasma levels of norepinephrine and epinephrine. During exercise, plasma norepinephrine and epinephrine levels were significantly elevated above control after acute but not after chronic treatment. These observations do not support the hypothesis that beta-adrenoceptor antagonist drugs lower blood pressure in hypertensive man through a sympatholytic mechanism in he central nervous system or at peripheral presynaptic receptors.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6160323     DOI: 10.1097/00005344-198011000-00003

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  6 in total

Review 1.  Exercise metabolism and beta-blocker therapy. An update.

Authors:  A Head
Journal:  Sports Med       Date:  1999-02       Impact factor: 11.136

2.  Propranolol and beta-adrenergic receptor blocking drugs in the treatment of hypertension.

Authors:  B N Prichard
Journal:  Br J Clin Pharmacol       Date:  1982-01       Impact factor: 4.335

3.  Interaction between simvastatin and metoprolol with respect to cardiac beta-adrenoceptor density, catecholamine levels and perioperative catecholamine requirements in cardiac surgery patients.

Authors:  A Franka Nette; Getu Abraham; Fritz Rupert Ungemach; Reinhard Oertel; Wilhelm Kirch; Kirsten Leineweber; Friedrich-Wilhelm Mohr; Stefan Dhein
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2005-10-22       Impact factor: 3.000

4.  The effect of captopril and propranolol on the responses to posture and isometric exercise in patients with essential hypertension.

Authors:  M J Vandenburg; J M Holly; F J Goodwin; V L Sharman; F P Marsh
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

5.  Effects of a new long-acting beta-blocker bopindolol (LT 31-200) on blood pressure, plasma catecholamines, renin and cholesterol in patients with arterial hypertension.

Authors:  P van Brummelen; F R Bühler; F W Amann; P Bolli
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

6.  Unchanged peripheral sympathetic activity following withdrawal of chronic metoprolol treatment. A study of noradrenaline concentrations and kinetics in plasma.

Authors:  G Olsson; M Daleskog; P Hjemdahl; N Rehnqvist
Journal:  Br J Clin Pharmacol       Date:  1984-10       Impact factor: 4.335

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.